Literature DB >> 12465153

Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation.

Richard F Macko1, Allan C Gelber, Bradford A Young, Mark H Lowitt, Barbara White, Fredrick M Wigley, Simeon E Goldblum.   

Abstract

OBJECTIVE: To determine whether circulating concentrations of the counteradhesive proteins SPARC (secreted protein acidic and rich in cysteine) and thrombospondin-1 (TSP-1) are elevated in scleroderma (systemic sclerosis, SSc). The relationship of these counteradhesive proteins to measures of platelet and endothelial cell activation was examined.
METHODS: Plasma from 45 patients with SSc (26 limited form, 19 diffuse) and 22 age and sex matched controls was assayed for SPARC, TSP-1, beta-thromboglobulin (betaTG), and platelet factor 4 (PF4), 2 distinct platelet a-granule products, and soluble E-selectin, a marker of endothelial cell activation.
RESULTS: The mean (+/- SE) SPARC concentration was greater in patients with limited SSc (124.0 +/- 9.6 ng/ml) compared to controls (66.8 +/- 8.0 ng/ml) (p = 0.0005), whereas in patients with diffuse SSc (74.1 +/- 7.9 ng/ml) it was not. Elevated SPARC concentrations in the limited SSc group could not be ascribed to either platelet or endothelial cell activation. TSP-1 concentrations were also increased in SSc patients (n = 29) compared to controls (n = 11) (2.98 +/- 0.12 vs 2.4 +/- 0.21 log transformed ng/ml; p < 0.02). Unlike SPARC, TSP-1 concentrations correlated with both betaTG (r = 0.57, p = 0.0014) and PF4 (r = 0.41, p = 0.026) levels, indicating that increased TSP-1 could, in part, be explained through elevated platelet a-granule release in SSc patients. Plasma levels of betaTG, PF4, and E-selectin were each similarly elevated (p < 0.003) in patients with both limited and diffuse SSc compared to controls.
CONCLUSION: That circulating SPARC and TSP-1 are elevated in patients with SSc raises the possibility that counteradhesive proteins, which regulate vascular organization and remodeling, might contribute to the pathogenesis of SSc vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465153

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  30 in total

1.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow.

Authors:  Natasha M Rogers; David D Roberts; Jeffrey S Isenberg
Journal:  Ann Surg       Date:  2013-07       Impact factor: 12.969

Review 3.  Application of biomarkers to clinical trials in systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 4.  Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 5.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Authors:  Joanne E Murphy-Ullrich; Mark J Suto
Journal:  Matrix Biol       Date:  2017-12-27       Impact factor: 11.583

6.  Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation.

Authors:  Eileen M Bauer; Yan Qin; Thomas W Miller; Russell W Bandle; Gabor Csanyi; Patrick J Pagano; Philip M Bauer; Jurgen Schnermann; David D Roberts; Jeff S Isenberg
Journal:  Cardiovasc Res       Date:  2010-07-07       Impact factor: 10.787

Review 7.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

8.  Attenuation of fibrosis in vitro and in vivo with SPARC siRNA.

Authors:  Jiu-Cun Wang; Syeling Lai; Xinjian Guo; Xuefeng Zhang; Benoit de Crombrugghe; Sonali Sonnylal; Frank C Arnett; Xiaodong Zhou
Journal:  Arthritis Res Ther       Date:  2010-04-01       Impact factor: 5.156

9.  Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines.

Authors:  Pei-Suen Tsou; Bradley J Rabquer; Ray A Ohara; William A Stinson; Phillip L Campbell; M Asif Amin; Beatrix Balogh; George Zakhem; Paul A Renauer; Ann Lozier; Eshwar Arasu; G Kenneth Haines; Bashar Kahaleh; Elena Schiopu; Dinesh Khanna; Alisa E Koch
Journal:  Rheumatology (Oxford)       Date:  2015-12-24       Impact factor: 7.580

Review 10.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.